Main Conference Day 2 - PT (Pacific Time, GMT-08:00)
Main Conference Day 2 - PT (Pacific Time, GMT-08:00)
6:30am - 7:15am45 mins
Scientific Breakfast Briefing #1
Fun Run on San Diego Harbor- Meet at Registration Desk in Pacific Ballroom Foyer (45 minutes)
6:30am - 7:15am45 mins
Scientific Breakfast Briefing #2
Fun Run on San Diego Harbor- Meet at Registration Desk in Pacific Ballroom Foyer (45 minutes)
7:15am - 7:30am15 mins
Scientific Breakfast Briefing #1
Registration
7:15am - 7:30am15 mins
Scientific Breakfast Briefing #2
Registration
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #2
From VHH to Intact IgG: Overnight Solution-Based Epitope Mapping by Electron Density Topography
- Takashi Sato, PhD - Chief Scientist & Technical Architect, Life Science Product Division, Rigaku Corporation
8:10am - 8:15am5 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
Co-Chairs’ Remarks
- Jay Bhatt, PhD - Principal Scientist, Johnson & Johnson
- Dhaya Seshasayee, PhD - Director of Antibody Discovery, Genentech
8:10am - 8:15am5 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
Co-Chairs' Remarks
- Stephen Beers, PhD - Professor of Immunology and Immunotherapy, University of Southampton
- Robert Chen, PhD - Antibody Engineer, Chai Discovery
8:15am - 8:45am30 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins
- Meredith Hazen - Scientist 4, Department of Antibody Engineering, Genentech
8:15am - 8:45am30 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
Antibody Modulation of PD-1 Signalling at Microvillar T-cell Contacts
- Simon Davis, PhD - Professor of Molecular Immunology, University of Oxford
8:45am - 9:15am30 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
100+ Undruggable Targets Unlocked Through Parallel Engineering
- Kyle Doolan, PhD - Senior Director of R&D, Integral Molecular
8:45am - 9:15am30 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
High Co-crosslinking of Surface Proteins by Anti-carbohydrate Antibodies for Rapid Internalization and Efficient Payload Delivery
- Peter Sondermann - CSO, Tacalyx GmbH
9:15am - 9:45am30 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
Next-Generation Atlas™ Transgenic Mice: A Versatile Platform for Therapeutic Antibody Discovery
- Dan Rohrer, PhD - Chief Technology Officer, AbTherx
9:15am - 9:45am30 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
Engineering and Characterization of Novel CD19 Antibodies to Control B Cell Activation
- Katherine Susa, PhD - Principal Investigator, UCSF
9:45am - 10:30am45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
Networking Refreshment Break, Exhibit and Poster Viewing
9:50am - 10:05am15 mins
Technology Showcase Presentations in the Exhibit Hall
Technology Showcase TBA
10:05am - 10:25am20 mins
Technology Showcase Presentations in the Exhibit Hall
Technology Showcase TBA
10:30am - 11:00am30 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
HCAb Harbour Mice® and AI for Next-Generation Therapeutic Antibody Discovery
- Musheng Bao, PhD - Head of Biology, Nona Biosciences
10:30am - 11:00am30 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
Beyond Blockade: Precision Stripping of Membrane Proteins with SureTAC™
- Qi Liang, MD, PhD - Chief Development Officer, Laigo Bio
11:00am - 11:30am30 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
Advanced In Vivo Approaches in the Viral Immune Repertoire
- Patrick Wilson, PhD - Professor, Weill Cornell Medicine
11:00am - 11:30am30 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
Late Breaking Presentation
11:30am - 12:00pm30 mins
Track 1: Advanced In Vivo Approaches to Antibody Discovery
Late Breaking Presentation
11:30am - 12:00pm30 mins
Track 2: Antibody Engineering for Proximity-Based Approaches
Late Breaking Presentation
12:05pm - 12:35pm30 mins
Scientific Briefing 2
The Hidden Drivers of Antibody Success: Integrating Discovery, Developability, and Manufacturing
- Samantha Hullah, PhD - Executive Director, Biologics SME., Syngene
12:05pm - 12:35pm30 mins
Scientific Briefing 3
From Hit Selection to Functional Testing: Reducing Expression Bottlenecks in Antibody Discovery
- Russell Coleman - Director, Strain Engineering, Primrose Bio
12:05pm - 12:35pm30 mins
Scientific Briefing 5
The Missing Triage Step: Cell-Free Screening for Rapid, Low-Cost Antibody Hit Validation
- Aujan Mehregan - Inside Sales Manager, BD & Sales, Nuclera
12:35pm - 1:05pm30 mins
Scientific Briefing 1
Predictive Multi-Objective Antibody Optimization Powered by Millions of Quantitative Affinity Measurements
- David Younger, Ph.D. - Co-Founder & CEO, A-Alpha Bio
12:35pm - 1:05pm30 mins
Scientific Briefing 2
Cell Free Antibody Engineering: Accelerating Discovery and Screening with PUREfrex®
- Takashi Ebihara (Ebi), PhD - COO, GeneFrontier Corporation
12:35pm - 1:05pm30 mins
Scientific Briefing 4
IQVIA Scientific Briefing
1:05pm - 2:25pm80 mins
Networking Luncheon, Exhibit and Poster Viewing
Networking Luncheon, Exhibit and Poster Viewing
1:20pm - 1:40pm20 mins
Technology Showcase Presentations in the Exhibit Hall
Aurigene Technology Showcase
1:40pm - 2:00pm20 mins
Technology Showcase Presentations in the Exhibit Hall
Twist Technology Showcase
2:00pm - 2:10pm10 mins
Technology Showcase Presentations in the Exhibit Hall
Technology Showcase TBA
2:25pm - 2:30pm5 mins
Track 1: Engineering and Biological Principles for Cell Engagers
Co-Chairs’ Remarks
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
- Mitchell Ho, PhD - Senior Investigator, Laboratory of Molecular Biology, NIH NCI
2:25pm - 2:30pm5 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
Co-Chairs' Remarks
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- Franziska Mortensen, PhD - Associate Director, Genmab
2:30pm - 3:00pm30 mins
Track 1: Engineering and Biological Principles for Cell Engagers
Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer
- Udaya Rangaswamy, Ph.D. - Senior Scientist, Rondo therapeutics
2:30pm - 3:00pm30 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
AAV-mediated Delivery of an Intrabody Targeting TDP-43 for Amyotrophic Lateral Sclerosis Therapy
- Giulia De Sabbata, PhD - Director and Head of Discovery, VectorY Therapeutics
3:00pm - 3:30pm30 mins
Track 1: Engineering and Biological Principles for Cell Engagers
Development of a PRAME pMHC Targeted T Cell Engager for Solid Tumor Therapy
- Nicole Schirle Oakdale - Principal Scientist, Gilead Sciences, Inc
3:00pm - 3:30pm30 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
Dual-targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression after Peripheral Administration
- Yunxuan Xie - PhD Candidate, University of Michigan
3:30pm - 4:00pm30 mins
Track 1: Engineering and Biological Principles for Cell Engagers
Next-Generation Multi-Antigen EVOLVE T Cell Engager with Integrated CD2 Co-stimulation
- Mohamed Elshenawy, PhD - Senior Scientist, EvolveImmune Therapeutics
3:30pm - 4:00pm30 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
Translating Multivalent Antibody Designs into Potent Viral Neutralizers
- Jean-Philippe Julien, Ph.D. - Senior Scientist, Molecular Medicine, Hospital for Sick Children Research Inst
4:00pm - 4:45pm45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
Networking Refreshment Break, Exhibit and Poster Viewing
4:10pm - 4:30pm20 mins
Technology Showcase Presentations in the Exhibit Hall
Technology Showcase TBA
4:45pm - 5:15pm30 mins
Track 1: Engineering and Biological Principles for Cell Engagers
High-throughput Engineering of Bispecific Antibodies to Stimulate Macrophage-mediated Destruction of B-cell Lymphoma
- Kipp Weiskopf - Head of Antibody Therapeutics and Biologics, Beth Israel Deaconess Medical Center
4:45pm - 5:15pm30 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases
- Nasa Savory - Senior Scientist, Chugai Pharmaceutical Co., Ltd
5:15pm - 5:45pm30 mins
Track 1: Engineering and Biological Principles for Cell Engagers
Machine Learning Guided Design of Avidity- and Logic-Gated T Cell Engagers
- Ryan Henrici, M.D., Ph.D. - Senior Director, Translational Research, BigHat Biosciences
5:15pm - 5:45pm30 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
Beyond the Fold: Turning Protein Misfolding into Antibody Opportunity
- Natalie Galant - CEO, Paradox Immunotherapeutics
5:45pm - 6:15pm30 mins
Track 1: Engineering and Biological Principles for Cell Engagers
Rewriting the Safety-Efficacy Balance: Engineering Conditionally Activated TCEs for Solid Tumors.
- Aude Segaliny, PhD - VP of Research & Development, Amberstone Biosciences
5:45pm - 6:15pm30 mins
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology
Preclinical Non-oncology Projects: Axatilimab (for GVHD), Tafasitamab (anti CD19 for ITP) and Others in Development
- Yuejiao Xian, PhD - Principal Investigator, Incyte
6:15pm - 7:15pm60 mins
Networking Reception
Networking Reception
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。